A PHASE III, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED, ACTIVE-COMPARATOR STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINIETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA

Date Added
January 17th, 2020
PRO Number
Pro00091469
Researcher
W. Lloyd Clark

List of Studies

Keywords
Diabetes
Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS in patients with DME when treated every 24 weeks compared with intravitreal ranibizumab 0.5 mg every 4 weeks.

Institution
Palmetto
Recruitment Contact
Tiffany Swinford
8034045037
tswinford@palmettoretina.com



-- OR --